CBER director Peter Marks speaks at Charles River's 2023 Cell and Gene Summit Tour (Photo c/o Charles River)

March 1, 2023 01:55 PM ESTUpdated 04:01 PM

CBER director Peter Marks says FDA is growing to keep up with cell and gene therapies

Nicole DeFeudis

Editor

SOMERVILLE, MA — CBER director Peter Marks spelled out FDA’s plans to keep up with the fast-growing cell and gene therapy space on Tuesday, while also …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

CBER director Peter Marks says FDA is growing to keep up with cell and gene therapies

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

AbbVie finally enters obesity race with $350M upfront for Gubra’s amylin

Trump’s science crackdown hits rare disease research: ‘We need to sit down with Elon Musk’

At least seven drugmakers say they will participate in round two of IRA negotiations

Exclusive: Infectious disease doctors consider 'mini-ACIP' if RFK erodes CDC vaccine panel

Lilly joins molecular glue field with Magnet deal worth up to $1.25B

The perfect storm: Why everything is in place for 2025 to be the year of GxP AI

CBER di­rec­tor Pe­ter Marks says FDA is grow­ing to keep up with cell and gene ther­a­pies

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

CBER director Peter Marks says FDA is growing to keep up with cell and gene therapies